KACIE TEMPEL: Open Payments
NPI 1144651944 · ANCHORAGE, AK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,594 in 132 payments from 21 companies in 2025. Trend: 2023 $470 · 2024 $2,911 · 2025 $3,594
Food & beverage: $3,519Consulting: $75
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 36 | $1,291 |
| GENZYME CORPORATION | 12 | $376 |
| GlaxoSmithKline, LLC. | 21 | $365 |
| BioCryst US Sales Co., LLC | 11 | $269 |
| CSL Behring | 11 | $205 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $154 |
| Verona Pharma, Inc. | 5 | $145 |
| Genentech, Inc. | 1 | $135 |
| Amgen Inc. | 6 | $105 |
| ADMA BioManufacturing LLC | 4 | $75 |
Products named: TEZSPIRE, FASENRA, DUPIXENT, NUCALA, ORLADEYO, AIRSUPRA, Xolair, Ohtuvayre.
Industry payments across AK — which companies pay providers there.
